SEC Form 4 · accession 0000899243-16-025935
Aegerion Pharmaceuticals, Inc. · AEGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sandford D Smith
Director
Period of report
Jul 27, 2016
Accepted (ET)
Jul 29, 2016 · 4:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001338042
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 27, 2016 | M | 2,222 | — | A | 3,667 | D | |
| Common Stock | Jul 27, 2016 | F | 777 | $1.55 | D | 2,890 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Jul 27, 2016 | M | 2,222 | D | — | — | Common Stock | 2,222 | 8,888 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of common stock.
- F216.67% of the grant vested on January 27, 2016, and an additional 16.67% vested on July 27, 2016. Subject to the Reporting Person continuing to serve as a member of the board of Aegerion Pharmaceuticals, Inc., an additional 16.67% of the grant will vest on each of January 27, 2017; July 27, 2017; January 27, 2018; and August 21, 2018.